• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by NewAmsterdam Pharma Company N.V.

    2/14/25 4:50:34 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NAMS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    NewAmsterdam Pharma Co N.V.

    (Name of Issuer)


    Ordinary Shares, nominal value EUR0.12 per share

    (Title of Class of Securities)


    N62509109

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    N62509109


    1Names of Reporting Persons

    VIKING GLOBAL INVESTORS LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,978,534.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,978,534.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,978,534.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.5 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    N62509109


    1Names of Reporting Persons

    Viking Global Opportunities Parent GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,978,534.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,978,534.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,978,534.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.5 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    N62509109


    1Names of Reporting Persons

    Viking Global Opportunities GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,675,619.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,675,619.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,675,619.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.4 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    N62509109


    1Names of Reporting Persons

    Viking Global Opportunities Portfolio GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,675,619.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,675,619.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,675,619.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.4 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    N62509109


    1Names of Reporting Persons

    Viking Global Opportunities Illiquid Investments Sub-Master LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,675,619.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,675,619.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,675,619.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.4 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    N62509109


    1Names of Reporting Persons

    Viking Global Opportunities Drawdown GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,302,915.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,302,915.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,302,915.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.2 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    N62509109


    1Names of Reporting Persons

    Viking Global Opportunities Drawdown Portfolio GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,302,915.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,302,915.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,302,915.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.2 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    N62509109


    1Names of Reporting Persons

    Viking Global Opportunities Drawdown (Aggregator) LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,302,915.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,302,915.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,302,915.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.2 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    N62509109


    1Names of Reporting Persons

    HALVORSEN OLE ANDREAS
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NORWAY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,978,534.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,978,534.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,978,534.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.5 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    N62509109


    1Names of Reporting Persons

    Ott David C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,978,534.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,978,534.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,978,534.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.5 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    N62509109


    1Names of Reporting Persons

    Shabet Rose Sharon
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,978,534.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,978,534.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,978,534.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.5 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    NewAmsterdam Pharma Co N.V.
    (b)Address of issuer's principal executive offices:

    Gooimeer 2-35, Naarden, Netherlands, 1411 DC
    Item 2. 
    (a)Name of person filing:

    Viking Global Investors LP ("VGI"), Viking Global Opportunities Parent GP LLC ("Opportunities Parent"), Viking Global Opportunities GP LLC ("Opportunities GP"), Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"), Viking Global Opportunities Illiquid Investments Sub-Master LP ("VGOP"), Viking Global Opportunities Drawdown GP LLC ("VGOD GP"), Viking Global Opportunities Drawdown Portfolio GP LLC ("VGOD Portfolio GP"), Viking Global Opportunities Drawdown (Aggregator) LP ("VGOD"), O. Andreas Halvorsen, David C. Ott and Rose S. Shabet (collectively, the "Reporting Persons")
    (b)Address or principal business office or, if none, residence:

    The business address of each of the Reporting Persons is: 600 Washington Boulevard, Floor 11, Stamford, Connecticut 06901.
    (c)Citizenship:

    VGI is a Delaware limited partnership; Opportunities Parent, Opportunities GP, Opportunities Portfolio GP, VGOD GP and VGOD Portfolio GP are Delaware limited liability companies; VGOP and VGOD are Cayman Islands exempted limited partnerships; O. Andreas Halvorsen is a citizen of Norway; and David C. Ott and Rose S. Shabet are citizens of the United States.
    (d)Title of class of securities:

    Ordinary Shares, nominal value EUR0.12 per share
    (e)CUSIP No.:

    N62509109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    VGI: 6,978,534 VGI provides managerial services to VGOP and VGOD. VGI has the authority to dispose of and vote the Ordinary Shares that VGOP and VGOD directly own. VGI does not directly own any Ordinary Shares. Based on Rule 13d-3 of the Act, VGI may be deemed to beneficially own the Ordinary Shares that VGOP and VGOD directly own. VGI beneficially owns 6,978,534 Ordinary Shares consisting of 4,675,619 Ordinary Shares directly owned by VGOP and 2,302,915 Ordinary Shares directly owned by VGOD. Opportunities Parent: 6,978,534 Opportunities Parent is the sole member of Opportunities GP, which has the authority to dispose of and vote the Ordinary Shares controlled by Opportunities Portfolio GP (which consists of the Ordinary Shares that VGOP directly owns), and is the sole member of VGOD GP, which has the authority to dispose of and vote the Ordinary Shares controlled by VGOD Portfolio GP (which consists of the Ordinary Shares that VGOD directly owns). Opportunities Parent does not directly own any Ordinary Shares. Based on Rule 13d-3 of the Act, Opportunities Parent may be deemed to beneficially own the Ordinary Shares that VGOP and VGOD directly own. Opportunities Parent beneficially owns 6,978,534 Ordinary Shares consisting of 4,675,619 Ordinary Shares directly owned by VGOP and 2,302,915 Ordinary Shares directly owned by VGOD. Opportunities GP: 4,675,619 Opportunities GP serves as the sole member of Opportunities Portfolio GP and has the authority to dispose of and vote the Ordinary Shares controlled by Opportunities Portfolio GP, which consists of the Ordinary Shares that VGOP directly owns. In addition, Opportunities GP is the general partner of each of Viking Global Opportunities Intermediate LP, Viking Global Opportunities III LP, and Viking Global Opportunities LP. Opportunities GP does not directly own any Ordinary Shares. Based on Rule 13d-3 of the Act, Opportunities GP may be deemed to beneficially own the Ordinary Shares that VGOP directly owns. Opportunities GP beneficially owns 4,675,619 Ordinary Shares consisting of 4,675,619 Ordinary Shares directly owned by VGOP. Opportunities Portfolio GP: 4,675,619 Opportunities Portfolio GP serves as the general partner of VGOP and has the authority to dispose of and vote the Ordinary Shares that VGOP directly owns. Opportunities Portfolio GP does not directly own any Ordinary Shares. Based on Rule 13d-3 of the Act, Opportunities Portfolio GP may be deemed to beneficially own the Ordinary Shares that VGOP directly owns. Opportunities Portfolio GP beneficially owns 4,675,619 Ordinary Shares consisting of 4,675,619 Ordinary Shares directly owned by VGOP. VGOP: 4,675,619 VGOP has the authority to dispose of and vote the 4,675,619 Ordinary Shares that it directly owns, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of Opportunities Portfolio GP, which provides managerial services to VGOP. Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests through VGOP. VGOD GP: 2,302,915 VGOD GP serves as the sole member of VGOD Portfolio GP and has the authority to dispose of and vote the Ordinary Shares controlled by VGOD Portfolio GP, which consists of the Ordinary Shares that VGOD directly owns. In addition, VGOD GP is the general partner of each of Viking Global Opportunities Drawdown (Internal) LP, Viking Global Opportunities Drawdown (Onshore) LP, and Viking Global Opportunities Drawdown (Offshore) LP. VGOD GP does not directly own any Ordinary Shares. Based on Rule 13d-3 of the Act, VGOD GP may be deemed to beneficially own the Ordinary Shares that VGOD directly owns. VGOD GP beneficially owns 2,302,915 Ordinary Shares consisting of 2,302,915 Ordinary Shares directly owned by VGOD. VGOD Portfolio GP: 2,302,915 VGOD Portfolio GP serves as the general partner of VGOD and has the authority to dispose of and vote the Ordinary Shares that VGOD directly owns. VGOD Portfolio GP does not directly own any Ordinary Shares. Based on Rule 13d-3 of the Act, VGOD Portfolio GP may be deemed to beneficially own the Ordinary Shares that VGOD directly owns. VGOD Portfolio GP beneficially owns 2,302,915 Ordinary Shares consisting of 2,302,915 Ordinary Shares directly owned by VGOD. VGOD: 2,302,915 VGOD has the authority to dispose of and vote the 2,302,915 Ordinary Shares that it directly owns, which power may be exercised by its general partner, VGOD Portfolio GP, and by VGI, an affiliate of VGOD Portfolio GP, which provides managerial services to VGOD. Viking Global Opportunities Drawdown (Offshore) LP (a Cayman Islands exempted limited partnership) and Viking Global Opportunities Drawdown (Internal) LP (a Delaware limited partnership), through its investment in Viking Global Opportunities Drawdown (Onshore) LP (a Delaware limited partnership), invest substantially all of their assets in VGOD. O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 6,978,534 Mr. Halvorsen, Mr. Ott and Ms. Shabet, as Executive Committee Members of Viking Global Partners LLC (general partner of VGI) and Opportunities Parent, have shared authority to dispose of and vote the Ordinary Shares beneficially owned by VGI and Opportunities Parent. None of Mr. Halvorsen, Mr. Ott and Ms. Shabet directly owns any Ordinary Shares. Based on Rule 13d-3 of the Act, each may be deemed to beneficially own the Ordinary Shares that VGOP and VGOD directly own. Mr. Halvorsen, Mr. Ott and Ms. Shabet each beneficially own 6,978,534 Ordinary Shares consisting of 4,675,619 Ordinary Shares directly owned by VGOP and 2,302,915 Ordinary Shares directly owned by VGOD.
    (b)Percent of class:

    The percentages set forth herein are based on 106,832,952 Ordinary Shares outstanding following the Issuer's underwritten public offering that closed on December 13, 2024, and after the underwriters exercised their option to purchase additional Ordinary Shares in full, as reported in the Issuer's prospectus on Form 424B5, filed with the Securities and Exchange Commission (the "Commission") on December 13, 2024, and the Issuer's current report on Form 8-K, filed with the Commission on December 13, 2024. VGI: 6.5 % Opportunities Parent: 6.5 % Opportunities GP: 4.4 % Opportunities Portfolio GP: 4.4 % VGOP: 4.4 % VGOD GP: 2.2 % VGOD Portfolio GP: 2.2 % VGOD: 2.2 % O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 6.5
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    VGI: 0 Opportunities Parent: 0 Opportunities GP: 0 Opportunities Portfolio GP: 0 VGOP: 0 VGOD GP: 0 VGOD Portfolio GP: 0 VGOD: 0 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 0

     (ii) Shared power to vote or to direct the vote:

    VGI: 6,978,534 Opportunities Parent: 6,978,534 Opportunities GP: 4,675,619 Opportunities Portfolio GP: 4,675,619 VGOP: 4,675,619 VGOD GP: 2,302,915 VGOD Portfolio GP: 2,302,915 VGOD: 2,302,915 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 6,978,534

     (iii) Sole power to dispose or to direct the disposition of:

    VGI: 0 Opportunities Parent: 0 Opportunities GP: 0 Opportunities Portfolio GP: 0 VGOP: 0 VGOD GP: 0 VGOD Portfolio GP: 0 VGOD: 0 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 0

     (iv) Shared power to dispose or to direct the disposition of:

    VGI: 6,978,534 Opportunities Parent: 6,978,534 Opportunities GP: 4,675,619 Opportunities Portfolio GP: 4,675,619 VGOP: 4,675,619 VGOD GP: 2,302,915 VGOD Portfolio GP: 2,302,915 VGOD: 2,302,915 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 6,978,534

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The response to Item 4 is incorporated by reference herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    VIKING GLOBAL INVESTORS LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of VIKING GLOBAL INVESTORS LP (1)(2)(3)
    Date:02/14/2025
     
    Viking Global Opportunities Parent GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)(3)
    Date:02/14/2025
     
    Viking Global Opportunities GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)(3)
    Date:02/14/2025
     
    Viking Global Opportunities Portfolio GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)(3)
    Date:02/14/2025
     
    Viking Global Opportunities Illiquid Investments Sub-Master LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP (1)(2)(3)
    Date:02/14/2025
     
    Viking Global Opportunities Drawdown GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown GP LLC (1)(2)(3)
    Date:02/14/2025
     
    Viking Global Opportunities Drawdown Portfolio GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown Portfolio GP LLC (1)(2)(3)
    Date:02/14/2025
     
    Viking Global Opportunities Drawdown (Aggregator) LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown (Aggregator) LP (1)(2)(3)
    Date:02/14/2025
     
    HALVORSEN OLE ANDREAS
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
    Date:02/14/2025
     
    Ott David C.
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of David C. Ott (2)
    Date:02/14/2025
     
    Shabet Rose Sharon
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Rose S. Shabet (3)
    Date:02/14/2025

    Comments accompanying signature:  (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).
    Exhibit Information

    EXHIBIT A - JOINT FILING AGREEMENT

    Get the next $NAMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NAMS

    DatePrice TargetRatingAnalyst
    10/20/2025$52.00Buy
    H.C. Wainwright
    8/25/2025$45.00Overweight
    Wells Fargo
    7/17/2025$27.00Neutral
    Goldman
    6/17/2025$42.00Buy
    Citigroup
    6/10/2025$44.00Buy
    Stifel
    6/4/2025$42.00Overweight
    Cantor Fitzgerald
    12/30/2024$48.00Buy
    H.C. Wainwright
    5/15/2024Buy
    TD Cowen
    More analyst ratings

    $NAMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Kooij Louise Frederika exercised 72,428 units of Ordinary Shares at a strike of $10.90 and sold $2,335,860 worth of Ordinary Shares (72,428 units at $32.25) (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    1/29/26 4:40:24 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Kooij Louise Frederika sold $2,415,843 worth of Ordinary Shares (72,572 units at $33.29) and exercised 72,572 units of Ordinary Shares at a strike of $10.90 (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    1/27/26 5:38:55 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Somaiya Mayur Ian exercised 100,000 units of Ordinary Shares at a strike of $9.26 and sold $3,260,618 worth of Ordinary Shares (100,000 units at $32.61) (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    1/22/26 5:24:59 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NAMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation

    NewAmsterdam REMBRANDT clinical trial to leverage Caristo CaRi-Heart® and CaRi-PlaqueTM technologies for coronary inflammation and plaque measurements and monitoring STAMFORD, Conn. and OXFORD, England, Oct. 14, 2025 /PRNewswire/ -- Caristo Diagnostics, on a mission to transform the diagnosis and treatment of cardiovascular disease, announced its role as the worldwide imaging core lab for NewAmsterdam Pharma's REMBRANDT Cardiovascular Imaging Trial – overseeing all coronary plaque and inflammation measurements and monitoring. The REMBRANDT trial, sponsored by NewAmsterdam Phar

    10/14/25 7:00:00 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund

    Frazier Life Sciences XII, L.P. will focus on creating and investing in pioneering companies developing novel therapeutics Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the closing of Frazier Life Sciences XII, L.P. (FLS XII), with over $1.3 billion in capital commitments. The oversubscribed fund received strong support from both longstanding and new limited partners. Consistent with prior FLS venture funds, FLS XII will primarily invest in company creation and early-stage private biopharmaceutical companies. "We appreciate the continued support of our limited partners, many of whom have been with us since the launch of o

    7/31/25 7:00:00 AM ET
    $ARQT
    $MIRM
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

    NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of Adele Gulfo as an independent director to its Board of Directors. Ms. Gulfo is an established pharmaceutical leader with over three decades of experience in the healthcare industry, distinguished by her expertise in global strategy, operations leadership, and the

    4/17/25 4:01:00 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NAMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on NewAmsterdam Pharma with a new price target

    H.C. Wainwright resumed coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $52.00

    10/20/25 8:45:44 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on NewAmsterdam Pharma with a new price target

    Wells Fargo initiated coverage of NewAmsterdam Pharma with a rating of Overweight and set a new price target of $45.00

    8/25/25 8:22:07 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on NewAmsterdam Pharma with a new price target

    Goldman initiated coverage of NewAmsterdam Pharma with a rating of Neutral and set a new price target of $27.00

    7/17/25 8:08:01 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NAMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Topper James N bought $15,639 worth of Ordinary Shares (660 units at $23.70) (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    9/17/25 5:22:34 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Topper James N bought $31,487 worth of Ordinary Shares (1,260 units at $24.99) (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    9/10/25 5:19:10 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Topper James N bought $11,294 worth of Ordinary Shares (471 units at $23.98) (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    8/13/25 4:49:54 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NAMS
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by NewAmsterdam Pharma Company N.V.

    SCHEDULE 13G - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    2/5/26 1:31:51 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by NewAmsterdam Pharma Company N.V.

    144 - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    1/20/26 4:17:30 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NewAmsterdam Pharma Company N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)

    1/9/26 8:00:27 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NAMS
    Leadership Updates

    Live Leadership Updates

    View All

    NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

    NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of Adele Gulfo as an independent director to its Board of Directors. Ms. Gulfo is an established pharmaceutical leader with over three decades of experience in the healthcare industry, distinguished by her expertise in global strategy, operations leadership, and the

    4/17/25 4:01:00 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

    enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

    5/15/24 4:05:00 PM ET
    $ENGN
    $NAMS
    $NKTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

    New board member brings deep expertise in cardiometabolic research, clinical development, and building successful biotech companies BioAge Labs, Inc., ("BioAge"), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, today announced the appointment of Michael Davidson, MD to the company's board of directors. "We are delighted to welcome Michael to BioAge's board of directors," said Kristen Fortney, PhD, CEO and co-founder of BioAge Labs. "His expertise as a physician and researcher in the field of cardiometabolism, deep experience in clinical development, and track record leading multiple successful compa

    4/9/24 8:00:00 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NAMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 5:35:24 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 4:00:47 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 10:28:58 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care